Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response

Laird, B. J.A., Fallon, M., Hjermstad, M. J., Tuck, S., Kaasa, S., Klepstad, P. and McMillan, D. C. (2016) Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response. Journal of Clinical Oncology, 34(23), pp. 2769-2775. (doi:10.1200/JCO.2015.65.7742) (PMID:27354484)

[img]
Preview
Text
129748.pdf - Published Version

575kB

Abstract

Purpose: Quality of life is a key component of cancer care; however, the factors that determine quality of life are not well understood. The aim of this study was to examine the relationship between quality of life parameters, performance status (PS), and the systemic inflammatory response in patients with advanced cancer. Methods: An international biobank of patients with advanced cancer was analyzed. Quality of life was assessed at a single time point by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-C30). PS was assessed by using the Eastern Cooperative Oncology Group (ECOG) classification. Systemic inflammation was assessed by using the modified Glasgow Prognostic Score (mGPS), which combines C-reactive protein and albumin. The relationship between quality of life parameters, ECOG PS, and the mGPS was examined. Results: Data were available for 2,520 patients, and the most common cancers were GI (585 patients [22.2%]) and pulmonary (443 patients [17.6%]). The median survival was 4.25 months (interquartile range, 1.36 to 12.9 months). Increasing mGPS (systemic inflammation) and deteriorating PS were associated with deterioration in quality-of-life parameters (P < .001). Increasing systemic inflammation was associated with deterioration in quality-of-life parameters independent of PS. Conclusion: Systemic inflammation was associated with quality-of-life parameters independent of PS in patients with advanced cancer. Further investigation of these relationships in longitudinal studies and investigations of possible effects of attenuating systemic inflammation are now warranted.

Item Type:Articles
Additional Information:Supported by Contract No. 037777 from the Norwegian Research Council and the European Union’s 6th Framework (biobank data collection).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMillan, Professor Donald
Authors: Laird, B. J.A., Fallon, M., Hjermstad, M. J., Tuck, S., Kaasa, S., Klepstad, P., and McMillan, D. C.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Journal of Clinical Oncology
Publisher:American Society of Clinical Oncology
ISSN:0732-183X
ISSN (Online):1527-7755
Published Online:27 June 2016
Copyright Holders:Copyright © 2016 American Society of Clinical Oncology
First Published:First published in Journal of Clinical Oncology 34(23): 2769-2775
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record